Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of “Buy” from Analysts

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have been assigned a consensus rating of “Buy” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $23.00.

A number of research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a research note on Thursday, November 14th. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st.

Aura Biosciences Stock Performance

NASDAQ:AURA opened at $7.65 on Thursday. Aura Biosciences has a 1 year low of $6.63 and a 1 year high of $12.38. The firm has a 50 day moving average of $8.02 and a 200-day moving average of $8.74. The stock has a market capitalization of $382.12 million, a P/E ratio of -4.42 and a beta of 0.29.

Insider Buying and Selling

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the sale, the insider now owns 304,692 shares in the company, valued at approximately $2,336,987.64. The trade was a 4.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold 23,045 shares of company stock worth $177,242 in the last quarter. Insiders own 5.40% of the company’s stock.

Institutional Trading of Aura Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the business. ProShare Advisors LLC bought a new stake in shares of Aura Biosciences during the 4th quarter valued at $127,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Aura Biosciences by 27.7% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 136,516 shares of the company’s stock valued at $1,122,000 after acquiring an additional 29,618 shares during the last quarter. Ensign Peak Advisors Inc raised its position in shares of Aura Biosciences by 43.3% during the 4th quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company’s stock valued at $3,212,000 after acquiring an additional 118,000 shares during the last quarter. Deutsche Bank AG raised its position in shares of Aura Biosciences by 56.7% during the 4th quarter. Deutsche Bank AG now owns 44,085 shares of the company’s stock valued at $362,000 after acquiring an additional 15,951 shares during the last quarter. Finally, Bank of America Corp DE raised its position in shares of Aura Biosciences by 20.5% during the 4th quarter. Bank of America Corp DE now owns 51,286 shares of the company’s stock valued at $422,000 after acquiring an additional 8,709 shares during the last quarter. Institutional investors own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.